{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The pathological hallmark of Parkinson's disease (PD) and several other neurodegenerative disorders is the deposition of intracytoplasmic neuronal inclusions termed Lewy bodies. The major components of Lewy bodies are amyloid fibrils of the protein a-synuclein (aS).",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay being described for the A30P variant, linking it to the formation of amyloid fibrils in Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Here we investigated if the disease-related mutation A30P not only modulates the kinetics of aS aggregation, but also alters the structure of amyloid fibrils. To this end we optimized the method of quenched hydrogen/deuterium exchange coupled to NMR spectroscopy and performed two-dimensional proton-detected highresolution magic angle spinning experiments.",
          "judgment": "Yes",
          "reasoning": "The general class of assay used (hydrogen/deuterium exchange coupled to NMR spectroscopy) effectively models the disease pathogenesis by examining the structural properties of amyloid fibrils, which are central to PD pathology.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The combined data indicate that the A30P mutation does not cause changes in the number, location and overall arrangement of b-strands in amyloid fibrils of aS. At the same time, several residues within the fibrillar core retain nano-second dynamics.",
          "judgment": "Yes",
          "reasoning": "The assay included basic controls and replicates, as evidenced by the detailed methodology and the comparison between wild-type and A30P aS fibrils. The study also references previous work validating the assay's use in the field.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Our data demonstrate that the fibrillar core of aS is not perturbed by the genetic mutation A30P.",
          "judgment": "No",
          "reasoning": "The study did not use known pathogenic or benign variants as controls in the assay for the A30P variant.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A30P mutation in SNCA was assessed for its impact on the structure of amyloid fibrils, a key feature in Parkinson's disease pathology. The study found no significant structural changes caused by the mutation, suggesting that the increased pathogenicity of A30P is unlikely due to altered fibril conformation. The evidence supports a pathogenic role but at a supporting strength due to the lack of variant controls in the assay."
    }
  ]
}